Funds from the upsized offering will support a trio of protein-degrading medicines in development for allergic conditions as ...

A combination of the shot and the immunotherapy Keytruda cut the risk of relapse or death by 42% in a landmark melanoma study ...

U.S. regulators have accepted a new submission for Vyglxia, offering the chance at a turnaround for another rare disease ...

The notice adds to growing concerns about the safety of knockoff weight loss drugs, which have remained popular despite FDA ...

Lower-than-expected sales of Xolair stood out as the Swiss drugmaker readies for an onslaught of generic competition for top ...

Hibsago is viewed as a potential “functional cure” for chronic infections and an important part of the British drugmaker’s ...

Shortly after winning a clearance in the skin disease dermatomyositis, brepocitinib posted results suggesting it might also ...

Today, a brief rundown of news involving Arcus Biosciences and Eli Lilly, as well as updates from TriGemX Bio and AstraZeneca that you may have missed. Eli Lilly is teaming up with Hong Kong-based ...

An experimental pill from Boston-based Rapport Therapeutics narrowly succeeded in a mid-stage study focused on bipolar mania, an outcome that analysts described as unexpected and a potential stepping ...

The launch prices of two-thirds of the new prescription drugs reviewed by the watchdog group ICER between 2022 and 2025 far exceeded the organization’s threshold of cost-effectiveness, according to a ...

Months after the FDA rejected its treatment for a rare light-sensitivity disease, the biotech claimed success in a Phase 3 ...

The acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a ...